目的：本研究旨在暸解以disulfiram協助酒癮病人行戒酒治療時，其肝功能和相關副作用之變化情形。 方法：根據文獻訂定收納個案的標準並簽署同意書，我們追蹤符合DSM-IV酒精依賴診斷的患者，使用disulfiram協助戒酒達三個月以上者，檢測其服用前、服用後三個月及六個月末之肝功能變化，包括SGOT、SGPT、γ-GT，並分析用藥前後之數值差異。同時，對於參與酒癮團體心理治療之患者，以自填問卷方式追蹤並了解其於使用disulfiram後兩週及四週之輕度副作用。 結果：共有203位病患使用disulfiram，其中52位完成三個月及13位完成六個月療程之追蹤。除一位病患因持續飲酒造成三個月末之γ-GT值比原來稍有上昇外，其餘無一造成肝功能數值惡化。三項肝功能平均指數於三個月比原有數值皆呈顯著下降(p<0.01)。在輕度副作用方面，共27位完成問卷，第四週之副作用比率比第二週明顯下降，以嗜睡、易疲倦為主。 結論：本臨床試驗初步顯示，使用disulfiram協助戒酒，在完成三個月及六個月追蹤的有限個案中，未見任何肝臟毒性。而在輕度副作用評估方面，患者報告隨著使用disulfiram的時間增長，其出現比率有下降趨勢。

　　　　　Objective: The purpose of this study was to examine liver-function test results following disulfiram administered as an adjunct to alcoholism treatment, as well as to evaluate the initial, less-serious adverse effects associated with the use of the drug. Methods: A six-month outpatient program was conducted using alcoholic patients who received 200 mg/day of disulfiram. Patients with initial transaminase levels (both SGOT and SGPT) lower than 100 U/L were allowed to enter the program. Subsequently, these patients underwent follow-up testing to establish both transaminase and γ-GT levels after three and six months on the drug. Patients participating in group psychotherapy were evaluated the less-serious adverse effects using a self-administered questionnaire at the end of the second and fourth weeks. Changes in liver function at baseline and three months were analyzed using the paired t-test after logistic transformation. Results: Fifty-two out of 205 patients using disulfiram completed a three-month follow-up, with 13 completing a six-month follow-up. The average sequential liver-function test results at three months were significantly lower than the respective baselines (p <0.05). All the indexes showed improvement except for one case with elevated γ-GT at six months owing to relapse into alcohol abuse. Analysis of age and gender distribution revealed no difference between patients who completed a three-month follow-up and those who dropped out before that time. The frequency of occurrence for the less-serious adverse effects of disulfiram treatment were decreased from the second to the fourth week for 27 patients, most commonly sleepiness and drowsiness. Conclusion: Disulfiram did not cause abnormal liver-function results in our modest patient sample during the follow-up period. The frequency of the common but less-serious adverse effects reduced with time during the initial four-week period.